← Leaderboards
David Lindsay
Leidos Biomedical Research, Inc.
$51,337,878
Attributed
$51,337,878
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $33.1M · FY2016–22$50M$37.5M$25M$12.5M$0
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$51,337,878 · 2
By mechanism
N01$51,337,878 · 2
Top collaborators
No co-investigators on record.
Most similar at Leidos Biomedical Research, Inc.
Same institution · by research overlap
- David Heimbrook$2,362,140,846
- Leonard Freedman$1,216,107,431
- Lynn Briscoe$495,968,635
- Matt Westerman$8,377,026
- Ethan Dmitrovsky$597,515,186
Others in their field
Top investigators on “Production”
- Eric S Lander · Whitehead Institute For Biomedical Res$568,626,051
- Bambra Strokes · Ppd Development Lp$526,656,217
- Richard A Gibbs · Baylor College Of Medicine$521,766,399
- Tracy L Nolen · Research Triangle Institute$451,761,218
- Sonia M Thomas · Research Triangle Institute$451,761,218
- David Heimbrook · Leidos Biomedical Research, Inc.$332,994,970
Research focus
ProductionClinical TrialsNational Institute Of Allergy And Infectious DiseaseMissionHiv VaccineResearch And DevelopmentTechnology TransferCommunicable DiseasesDisease OutbreaksVaccinesAntibodiesFutureClinical MaterialClinical ResearchDrug ProductionPrevention TrialProgramsPhase Ii Clinical TrialsNeutralizing Monoclonal AntibodiesClinicPharmaceutical PreparationsPhase I Clinical TrialsMediatingPhase Ii Trial
Grant awards (7)
NIAID- VRC HIV mAb-Research, Development, and Production to Support HIV Monoclonal Antibody Development$13,145,256
N01 · FY2022 · AI · contact PI
NIAID- VRC- Research, Development, and Production to Support Clinical Trials for HIV Vaccines.$10,143,220
N01 · FY2022 · AI · contact PI
NIAID-VRC- Rapid Manufacturing Response$9,822,408
N01 · FY2022 · AI · contact PI
Anti-HIV Broadly Neutralizing Monoclonal Antibody (bnAbs) Drug Substance (DS) Clinical Trial Material Production and Release$5,897,683
N01 · FY2019 · CA · contact PI
Anti-HIV Broadly Neutralizing Monoclonal Antibody (bnAbs) Drug Substance (DS) Clinical Trial Material Production and Release$6,969,685
N01 · FY2018 · CA · contact PI
Research, Development and Production to Support Clinical Trials for HIV Vaccines$59,626
N01 · FY2018 · CA · contact PI
Research, Development and Production to Support Clinical Trials for HIV Vaccines$5,300,000
N01 · FY2016 · CA · contact PI